[Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer].
OBJECTIVE
The prognosis of stage I-II non-small cell lung cancer (NSCLC) after operation is related to many factors. Apoptosis-related oncogenes play an important role in occurrence and development of tumors. This study was to investigate the expression and prognostic significance of representative apoptosis-related oncogenes (Survivin, Bcl-2, Bax, and Fas) in stage I-II NSCLC.


METHODS
The expression of Survivin, Bcl-2, Bax, and Fas in 115 specimens of stage I-II NSCLC and 20 specimens of non-tumor lung tissue were detected by SP immunohistochemistry.


RESULTS
The positive rates of Survivin and Bcl-2 were significantly higher in NSCLC than in non-tumor lung tissues (62.61% vs. 10.00%, P<0.001; 49.57% vs. 15.00%, P<0.05); the positive rates of Bax and Fas were significantly lower in NSCLC than in non-tumor lung tissues (31.30% vs. 65.00%, P<0.05; 46.96% vs. 80.00%, P<0.05). TNM stage and positive expression of Survivin were independent prognostic factors of stage I-II NSCLC (P<0.01). The survival time of patients was significantly shorter in Survivin-positive group than in Survivin-negative group [(33+/-7) months vs. (52+/-9) months, P<0.05].


CONCLUSIONS
Apoptosis-related oncogenes may have some impacts on the occurrence and development of stage I-II NSCLC. TNM stage and positive expression of Survivin are independent prognostic factors.
Wang
Dao-Feng
DF
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China.
Zeng
Can-Guang
CG
Lin
Yong-Bin
YB
Hou
Jing-Hui
JH
Zhu
Zhi-Hua
ZH
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D018287:Carcinoma, Large Cell / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D015996:Survival Rate; D000077022:Survivin; D051028:bcl-2-Associated X Protein / Q000378:metabolism; D019014:fas Receptor
C107489:BIRC5 protein, human; C491901:FAS protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D018124:Receptors, Tumor Necrosis Factor; D000077022:Survivin; D051028:bcl-2-Associated X Protein; D019014:fas Receptor